Falsified Medical Products in Francophone Sub-Saharan Africa

By Staff Writer

October 9, 2023

The Challenges of Substandard Medical Products

Substandard and falsified (SF) medical products pose a significant threat to public health. These products can cause harm, fuel resistance to genuine treatments, and undermine health systems. In Francophone sub-Saharan Africa, SF products are increasingly prevalent, largely due to the limited capacity of National Regulatory Authorities (NRAs) to fulfil their functions.

Solutions and Initiatives

Several initiatives are helping to combat this issue. The African Union (AU) and the World Health Organization (WHO) have launched the African Medicine Regulatory Harmonization (AMRH) Initiative and the African Medicines Agency (AMA). These initiatives aim to strengthen regulation and supply of quality-assured medical products.

The WHO Member State Mechanism is another important initiative, focusing on tackling SF medical products from a public health approach. Unfortunately, no NRAs in French-speaking Africa have yet achieved a maturity level 3. This indicates a stable, well-functioning, and integrated regulatory system. However, Burkina Faso, Niger, Ivory Coast, and Senegal are actively engaged in this process and could progress rapidly.

Academia also plays a crucial role in combating SF medical products. Universities like the University of Senegal Cheikh Anta Diop and the University of Douala in Cameroon have implemented a curriculum guide on SF medical products, educating future specialists and policymakers.

Procurement agencies, such as the Ecumenical Pharmaceutical Network (EPN), have also engaged in surveillance of SF medical products, integrating their data with national post-marketing surveillance of NRAs.

In conclusion, preventing, detecting, and responding to SF medical products remains a challenge in Francophone sub-Saharan Africa. However, through collective efforts and initiatives, progress is being made.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.